Aptevo Therapeutics reported a net loss of $6.5 million for the quarter ended September 30, 2026, and a net loss attributable to common stockholders of $9.3 million after accounting for a $2.8 million deemed dividend. The company's cash position decreased significantly from $21.6 million at the end of 2025 to $8.3 million as of September 30, 2026, primarily due to $19.1 million used in operating activities.
Aptevo Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a business update on its clinical pipeline. The company highlighted a 79% remission rate for its lead candidate mipletamig in high-risk TP53-mutated AML patients, which is nearly double the historical benchmark for standard-of-care treatments.
“We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline. We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
“As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
Aptevo Therapeutics entered into warrant inducement agreements resulting in the cash exercise of existing warrants for 2,777,778 shares at a reduced price of $1.08 per share. The company received $3.0 million in gross proceeds and issued new 'reload' warrants for up to 13,888,890 additional shares to the participating holders. Proceeds will be used for working capital and general corporate purposes.